AllRock Bio

Executive Summary

AllRock Bio is a newly formed private biotech headquartered in Boston, focused on developing innovative small-molecule therapies for cardiopulmonary diseases, including pulmonary hypertension and interstitial lung diseases. Founded in 2024 by a team with a proven track record in drug development and company-building (having previously founded and exited a successful biotech venture), AllRock Bio has rapidly advanced a late-stage pipeline. The company aims to address significant unmet medical needs in conditions where current treatments are limited, leveraging deep disease biology expertise and a patient-centric approach. With a lead program already in Phase 3, AllRock Bio is positioned to deliver transformative therapies that could improve outcomes for patients suffering from these debilitating cardiopulmonary disorders. The leadership's prior success in bringing drugs to market and building shareholder value underscores the company's potential to execute on its development and commercialization strategy.

Upcoming Catalysts (preview)

• Q4 2027Phase 3 topline data readout for lead cardiopulmonary program55% success
• Q2 2028Regulatory filing (NDA) for lead candidate50% success
• Q2 2027Potential partnership or licensing deal for pipeline asset30% success